Physician profile
Robert D Cunningham, JR.
NPI 1306855861
$2,323.35
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $178 · 2021: $719 · 2022: $544 · 2023: $266 · 2024: $15.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $545.57 | 2019-2023 | |
| Allergan, INC. | $436.20 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $350.42 | 2019-2021 | |
| Sight Sciences, INC. | $166.32 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $161.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $135.87 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $128.31 | 2022-2023 | Miebo |
| Janssen Pharmaceuticals, INC | $73.07 | 2022 | |
| Lilly USA, LLC | $66.28 | 2019 | |
| Alcon Vision LLC | $58.50 | 2022-2023 | Eysuvis |
| Sun Pharmaceutical Industries INC. | $50.79 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $45.00 | 2021-2022 | |
| Oyster Point Pharma, INC. | $36.88 | 2022-2023 | Tyrvaya |
| Sumitomo Pharma America, INC. | $15.06 | 2024 | Myfembree |
| Mallinckrodt Hospital Products INC. | $14.95 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.24 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.92 | 2021 | |
| Horizon Therapeutics Plc | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.